Evidence map›Paper›PMID 31921941›Full record

ArticleBone reports2020

FGF21, not GCN2, influences bone morphology due to dietary protein restrictions.

Margaret A McNulty, Brad A Goupil, Diana C Albarado, Teresa Castaño-Martinez, Thomas H Ambrosi, Spela Puh, Tim J Schulz, Annette Schürmann, Christopher D Morrison, Thomas Laeger

Open access · goldAbstract read
In one paragraph

Article in Bone reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Margaret A McNultyDepartment of Anatomy, Cell Biology, & Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Brad A GoupilDepartment of Pathobiological Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, LA 70803, USA.
Diana C AlbaradoPennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
Teresa Castaño-MartinezDepartment of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Thomas H AmbrosiDepartment of Adipocyte Development and Nutrition, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany.
Spela PuhDepartment of Adipocyte Development and Nutrition, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany.
Tim J SchulzGerman Center for Diabetes Research, München-Neuherberg, Germany.
Annette SchürmannDepartment of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Christopher D MorrisonPennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
Thomas LaegerPennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
Pennington Biomedical Research Center · USLouisiana State University · USUniversity of Potsdam · DEDeutsches Diabetes-Zentrum e.V. · DEGerman Institute of Human Nutrition · DEStanford Medicine · US

Funding

Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Sujoy Ghosh · 2005 to 2026
$26.5M
FGF21 is an endocrine signal of protein restrictionR01DK105032 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI MORRISON, CHRISTOPHER D · 2016 to 2019
$1.4M
NIDDK NIH HHS P30 DK072476NIDDK NIH HHS R01 DK105032
6 · The paper itself

Abstract

backgroundDietary protein restriction is emerging as an alternative approach to treat obesity and glucose intolerance because it markedly increases plasma fibroblast growth factor 21 (FGF21) concentrations. Similarly, dietary restriction of methionine is known to mimic metabolic effects of energy and protein restriction with FGF21 as a required mechanism. However, dietary protein has been shown to be required for normal bone growth, though there is conflicting evidence as to the influence of dietary protein restriction on bone remodeling. The purpose of the current study was to evaluate the effect of dietary protein and methionine restriction on bone in lean and obese mice, and clarify whether FGF21 and general control nonderepressible 2 (GCN2) kinase, that are part of a novel endocrine pathway implicated in the detection of protein restriction, influence the effect of dietary protein restriction on bone.

methodsAdult wild-type (WT) or

resultsIn WT mice the 27-week LP diet significantly reduced cortical bone, and this effect was enhanced by deletion of

conclusionsThis study provides direct evidence of a reduction in bone following long-term dietary protein restriction in a mouse model, effects that appear to be mediated by FGF21.

Indexed as

Dietary restrictionFGF21GCN2Microcomputed tomographyProtein restriction

Identifiers

PMID31921941
PMCPMC6950640
OpenAlexW2997333505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.